logo BDSP

Base documentaire


  1. The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma.

    Article - En anglais

    Markov modeling was used to evaluate the cost-effectiveness of octreotide in treating carcinoid syndrome and VIPoma.

    For each condition, using octreotide was associated with doubled survival time.

    Octreotide was cost-effective for treating carcinoid tumor ($752 per additional year of life, two additional years on average), and cost saving for VIPoma.

    Mots-clés Pascal : Carcinoïde syndrome, VIP, Octréotide, Acétate, Méthodologie, Chimiothérapie, Traitement, Analyse coût efficacité, Homme, Epidémiologie, Economie santé, Endocrinopathie, Paranéoplasique syndrome, Neuropeptide, Hormone peptide, Hormone gastrointestinale

    Mots-clés Pascal anglais : Carcinoid syndrome, VIP, Octreotide, Acetate, Methodology, Chemotherapy, Treatment, Cost efficiency analysis, Human, Epidemiology, Health economy, Endocrinopathy, Paraneoplastic syndrome, Neuropeptide, Peptide hormone, Gastrointestinal hormone

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0533163

    Code Inist : 002B02R01. Création : 23/03/1999.